Trevena Announces Receipt of Nasdaq Delisting Notification
October 04, 2024 16:05 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Reverse Stock Split
August 08, 2024 16:05 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Reports Second Quarter 2024 Results and Provides Business Update
August 08, 2024 07:00 ET
|
Trevena, Inc.
TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism...
Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing
July 08, 2024 09:15 ET
|
Trevena, Inc.
Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and commercialization milestones Trevena further...
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models
June 20, 2024 07:00 ET
|
Trevena, Inc.
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant,...
Trevena Reports First Quarter 2024 Results and Provides Business Update
May 15, 2024 07:00 ET
|
Trevena, Inc.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances,...
Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update
April 01, 2024 07:00 ET
|
Trevena, Inc.
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial...
Trevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant Exercise
December 28, 2023 14:00 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise
December 27, 2023 09:10 ET
|
Trevena, Inc.
CHESTERBROOK, Pa., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Trevena Inc. (“Trevena” or the “Company”) (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual Meeting
December 04, 2023 07:02 ET
|
Trevena, Inc.
-- Presentation highlighted promising results of TRV045 in nonclinical models of neuropathic pain including mechanical and cold-stimulus evoked nociceptive pain in a dose-related manner TRV045...